Pharmacodynamic stimulation of thrombogenesis by angiotensin (1-7) in recurrent ovarian cancer patients receiving gemcitabine and platinum-based chemotherapy

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 4, 2013, Pages 965-972

  Pham, Huyen ^a   Schwartz, Benjamin M ^b   Delmore, James E ^c   Reed, Eddie ^d   Cruickshank, Scott ^e   Drummond, Leanne ^f   Rodgers, Kathleen E ^g   Peterson, Kainoa J ^f   Dizerega, Gere S ^a,f  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Cleveland Office of McGlinchey Stafford PLLC   (United States)

^c Associates in Women's Health   (United States)

^d USA Mitchell Cancer Institute   (United States)

^e Cruickshank and Associates   (United States)

^f US Biotest   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

A(1 7); Carboplatin; Cisplatin; Gemcitabine; Thrombocytopenia; Thrombocytosis

Indexed keywords

ANGIOTENSIN[1-7]; CARBOPLATIN; CISPLATIN; GEMCITABINE; PLACEBO; ANGIOTENSIN I; ANGIOTENSIN I (1 7); ANGIOTENSIN I (1-7); ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; PEPTIDE FRAGMENT;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BACKACHE; BLOOD CLOTTING; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; DYSURIA; EPISTAXIS; FATIGUE; FEMALE; HEADACHE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OROPHARYNX PAIN; OVARY CANCER; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; BONE MARROW; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; MIDDLE AGED; OVARY TUMOR; PHASE 2 CLINICAL TRIAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN I; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CARBOPLATIN; CISPLATIN; DEOXYCYTIDINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PEPTIDE FRAGMENTS; THROMBOCYTOPENIA;

MLCS; MLOWN;

EID: 84878826017     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2089-x     Document Type: Article

References (28)

1. Shen X, Bernstein K (2011) The peptide network regulated by angiotensin converting enzyme (ACE) in hematopoiesis. Cell Cycle 10(9):1-7
2. Haznedaroglu C, Ozturk MA (2003) Towards the understanding of the local hematopoietic bone marrow renin-angiotensin system. Int J Biochem Cell Biol 35:867-880 (Pubitemid 36379328)
3. Strawn WB, Richmond RS, Ann TE et al (2004) Renin-angiotensin system expression in rat bone marrow haematopoietic and stromal cells. Br J Haematol 126:120-126 (Pubitemid 38859492)
4. Rodgers KE, Xiong S, diZerega GS (2002) Accelerated recovery from irradiation injury by angiotensin peptides. Cancer Chemother Pharmacol 49:403-411 (Pubitemid 34439342)
5. Rodgers KE, Xiong S, diZerega GS (2003) Effect of angiotensin II and angiotensin (1-7) on white blood cell recovery after intravenous chemotherapy. Cancer Chemother Pharmacol 51:97-106 (Pubitemid 36259469)
6. Rodgers KE, Xiong S, Steers R et al (2000) Effect of angiotensin II on hematopoietic progenitor cell proliferation. Stem Cells 18:287-294 (Pubitemid 30602276)
7. Heringer-Walther S, Eckert K, Schumacher SM et al (2009) Angiotensin-(1-7) stimulates hematopoietic progenitor cells in vitro and in vivo. Haematologica 94:857-860
8. Nio Y, Matsubara H, Murasawa S et al (1995) Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. J Clin Invest 95:46-54
9. Gallinat S, Yu M, Dorst A et al (1998) Sciatic nerve transection evokes lasting up-regulation of angiotensin AT2 and AT1 receptor mRNA in adult rat dorsal root ganglia and sciatic nerves. Brain Res Mol Brain Res 57:111-122 (Pubitemid 28279567)
10. Zambidis ET, Park TS, Yu W et al (2008) Expression of angiotensin-converting enzyme (CD143) identifies and regulates primitive hemangioblasts derived from human pluripotent stem cells. Blood 112:3601-3614
11. Rodgers KE, Oliver J, diZerega GS (2006) Phase I/II dose escalation study of angiotensin 1-7 [A(1-7)] administered before and after chemotherapy in patients with newly diagnosed breast cancer. Cancer Chemother Pharmacol 57:559-568 (Pubitemid 43237839)
12. Liu HW, Cheng B, Li JF et al (2009) Characterization of angiotensin-converting enzyme expression during epidermis morphogenesis in humans: a potential marker for epidermal stem cells. Br J Dermatol 160:250-258
13. Tavian M, Biasch K, Sinka L et al (2010) Embryonic origin of human hematopoiesis. Int J Dev Biol 54:1061-1065
14. Jokubaitis VJ, Sinka L, Driessen R et al (2008) Angiotensin-converting enzyme (CD143) marks hematopoietic stem cells in human embryonic, fetal, and adult hematopoietic tissues. Blood 111:4055-4063
15. Sinka L, Biasch K, Khazaal I et al (2012) Angiotensin-converting enzyme (CD143) specifies emerging lympho-hematopoietic progenitors in the human embryo. Blood, prepublished 26 January 2012
16. Brunton LL, Lazo JS, Parker KL (2006) Renin and Angiotensin, in Goodman & Gilman's The Pharmacological Basis of Therapeutics 11 edn. NY, Edwin Jackson, New York, pp 789-821
17. Ellefson DD, Espinoza T, Roda N et al (2004) Synergistic effects of co-administration of angiotensin 1-7 and neupogen on hematopoietic recovery in mice. Cancer Chemother Pharmacol 53:15-24 (Pubitemid 38161184)
18. Rodgers KE, Espinoza T, Roda N et al (2012) Accelerated hematopoietic recovery with angiotensin-(1-7) after total body radiation. Int J Radiat Biol 88:466-476
19. Lorusso D, Di Stefano A, Fanfani F et al (2006) Role of gemcitabine in ovarian cancer treatment. Ann Oncol 17:188-194 (Pubitemid 43985232)
20. Hryniuk W, Goodyear M (1990) The calculation of received dose intensity. J Clin Oncol 8:1935-1937
21. Longo D, Duffey P, DeVita V et al (1991) The calculation of actual or received dose intensity: a comparison of published methods. J Clin Oncol 9:2042-2051
22. Bewick V, Cheek L, Ball J (2004) Statistics review 10: further nonparametric methods. Crit Care 8:196-199 (Pubitemid 38735700)
23. Fanucchi M, Glaspy J, Crawford J et al (1997) Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 336:404-409 (Pubitemid 27081903)
24. Basser RL, Rasko J, Clarke K et al (1997) Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood 89:3118-3128
25. Davis TA, Landauer MR, Mog SR et al (2010) Timing of captopril administration determines radiation protection or radiation sensitization in a murine model of total body irradiation. Exp Hematol 38:270-281
26. Chisi JE, Briscoe CV, Ezan E et al (2000) Captopril inhibits in vitro and in vivo the proliferation of primitive haematopoietic cells induced into cell cycle by cytotoxic drug administration or irradiation but has no effect on myeloid leukaemia cell proliferation. Br J Haematol 109:563-570 (Pubitemid 30415183)
27. Charrier S, Michaud A, Badaoui S et al (2004) Inhibition of angiotensin I-converting enzyme induces radioprotection by preserving murine hematopoietic short-term reconstituting cells. Blood 104:978-985 (Pubitemid 39038016)
28. Australian Government Department of Health and Ageing Schedule of Pharmaceutical Benefits Summary of Changes Document Effective 1 September 2011, pp 23-26